


### Amendments to the Claims

1-6 (Canceled)

7. (Currently Amended)

A compound of formula I



or a pharmaceutically acceptable salt, wherein:

A is

a) an aryl ring selected from phenyl, wherein any stable phenyl ring atom is independently unsubstituted or substituted with

- 1) halogen,
- 2) NO<sub>2</sub>,
- 3) CN,
- 4) CR<sup>46</sup>=C(R<sup>47</sup>R<sup>48</sup>)<sub>2</sub>,
- 5) C≡C R<sup>46</sup>,
- 6) (CR<sup>i</sup>R<sup>j</sup>)<sub>r</sub>OR<sup>46</sup>,
- 7) (CR<sup>i</sup>R<sup>j</sup>)<sub>r</sub>N(R<sup>46</sup>R<sup>47</sup>),
- 8) (CR<sup>i</sup>R<sup>j</sup>)<sub>r</sub>C(O)R<sup>46</sup>,
- 9) (CR<sup>i</sup>R<sup>j</sup>)<sub>r</sub>C(O)OR<sup>46</sup>,
- 10) (CR<sup>i</sup>R<sup>j</sup>)<sub>r</sub>R<sup>46</sup>,
- 11) (CR<sup>i</sup>R<sup>j</sup>)<sub>r</sub>S(O)O-2R<sup>61</sup>,
- 12) (CR<sup>i</sup>R<sup>j</sup>)<sub>r</sub>S(O)O-2N(R<sup>46</sup>R<sup>47</sup>),
- 13) OS(O)O-2R<sup>61</sup>,
- 14) N(R<sup>46</sup>)C(O)R<sup>47</sup>,
- 15) N(R<sup>46</sup>)S(O)O-2R<sup>61</sup>,
- 16) (CR<sup>i</sup>R<sup>j</sup>)<sub>r</sub>N(R<sup>46</sup>)R<sup>61</sup>,
- 17) (CR<sup>i</sup>R<sup>j</sup>)<sub>r</sub>N(R<sup>46</sup>)R<sup>61</sup>OR<sup>47</sup>,
- 18) (CR<sup>i</sup>R<sup>j</sup>)<sub>r</sub>N(R<sup>46</sup>)(CR<sup>k</sup>R<sup>l</sup>)<sub>s</sub>C(O)N(R<sup>47</sup>R<sup>48</sup>),
- 19) N(R<sup>46</sup>)(CR<sup>i</sup>R<sup>j</sup>)<sub>r</sub>R<sup>61</sup>,

20)  $\text{N}(\text{R}^{46})(\text{CR}^i\text{R}^j)_r\text{N}(\text{R}^{47}\text{R}^{48})$ ,

21)  $(\text{CR}^i\text{R}^j)_r\text{C}(\text{O})\text{N}(\text{R}^{47}\text{R}^{48})$ ,

22) oxo,

b) a heteroaryl ring selected from the group consisting of pyridine, pyrimidine, pyrazine, pyridazine, indole, pyrrolopyridine, benzimidazole, benzoxazole, benzothiazole, and benzoxadiazole

wherein any stable S heteroaryl ring atom is unsubstituted or mono- or di-substituted with oxo, and any stable C or N heteroaryl ring atom is independently unsubstituted or substituted with

1) halogen,

2)  $\text{NO}_2$ ,

3)  $\text{CN}$ ,

4)  $\text{CR}^{46}=\text{C}(\text{R}^{47}\text{R}^{48})_2$ ,

5)  $\text{C}\equiv\text{C R}^{46}$ ,

6)  $(\text{CR}^i\text{R}^j)_r\text{OR}^{46}$ ,

7)  $(\text{CR}^i\text{R}^j)_r\text{N}(\text{R}^{46}\text{R}^{47})$ ,

8)  $(\text{CR}^i\text{R}^j)_r\text{C}(\text{O})\text{R}^{46}$ ,

9)  $(\text{CR}^i\text{R}^j)_r\text{C}(\text{O})\text{OR}^{46}$ ,

10)  $(\text{CR}^i\text{R}^j)_r\text{R}^{46}$ ,

11)  $(\text{CR}^i\text{R}^j)_r\text{S}(\text{O})_{0-2}\text{R}^{61}$ ,

12)  $(\text{CR}^i\text{R}^j)_r\text{S}(\text{O})_{0-2}\text{N}(\text{R}^{46}\text{R}^{47})$ ,

13)  $\text{OS}(\text{O})_{0-2}\text{R}^{61}$ ,

14)  $\text{N}(\text{R}^{46})\text{C}(\text{O})\text{R}^{47}$ ,

15)  $\text{N}(\text{R}^{46})\text{S}(\text{O})_x\text{R}^{61}$ ,

16)  $(\text{CR}^i\text{R}^j)_r\text{N}(\text{R}^{46})\text{R}^{61}$ ,

17)  $(\text{CR}^i\text{R}^j)_r\text{N}(\text{R}^{46})\text{R}^{61}\text{OR}^{47}$ ,

18)  $(\text{CR}^i\text{R}^j)_r\text{N}(\text{R}^{46})(\text{CR}^k\text{R}^l)_s\text{C}(\text{O})\text{N}(\text{R}^{47}\text{R}^{48})$ ,

19)  $\text{N}(\text{R}^{46})(\text{CR}^i\text{R}^j)_r\text{R}^{61}$ ,

20)  $\text{N}(\text{R}^{46})(\text{CR}^i\text{R}^j)_r\text{N}(\text{R}^{47}\text{R}^{48})$ ,

21)  $(\text{CR}^i\text{R}^j)_r\text{C}(\text{O})\text{N}(\text{R}^{47}\text{R}^{48})$ , or

22) oxo, or

c) a 4-, 5- or 6-membered heterocyclic ring containing 1 or 2 nitrogen atoms, unsubstituted, mono-substituted or di-substituted with  $\text{C}_1\text{-}\text{C}_6$  alkyl;

Y is  $\text{CH}_2$ ,  $\text{NR}^{53}$ ,  $\text{NC}(\text{O})\text{R}^{53}$ ,  $\text{S}(\text{O})_{0-2}$  or O;



G is  $\text{H}_2$  or O;

R<sup>a</sup>, R<sup>b</sup>, R<sup>i</sup>, R<sup>j</sup>, R<sup>k</sup>, and R<sup>l</sup> are independently selected from the group consisting of:

- 1) hydrogen,
- 2) C<sub>1</sub>-C<sub>6</sub> alkyl,
- 3) halogen,
- 4) aryl,
- 5) R<sup>80</sup>,
- 6) C<sub>3</sub>-C<sub>10</sub> cycloalkyl, and
- 7) OR<sup>4</sup>,

said alkyl, aryl, and cycloalkyl being unsubstituted, monosubstituted with R<sup>7</sup>, disubstituted with R<sup>7</sup> and R<sup>15</sup>, trisubstituted with R<sup>7</sup>, R<sup>15</sup> and R<sup>16</sup>, or tetrasubstituted with R<sup>7</sup>, R<sup>15</sup>, R<sup>16</sup> and R<sup>17</sup>;  
R<sup>1</sup> is independently selected from:

- 1) hydrogen,
- 2) halogen,
- 3) CN,
- 4) OR<sup>40</sup>,
- 5) N(R<sup>40</sup>R<sup>41</sup>),
- 6) C(O)OR<sup>40</sup>,
- 7) R<sup>81</sup>,
- 8) S(O)<sub>0-2</sub>R<sup>6</sup>,
- 9) N(R<sup>40</sup>)(CR<sup>a</sup>R<sup>b</sup>)<sub>n</sub>R<sup>6</sup>, wherein R<sup>6</sup> = R<sup>83</sup>,
- 10) N(R<sup>40</sup>)(CR<sup>a</sup>R<sup>b</sup>)<sub>n</sub>N(R<sup>41</sup>R<sup>42</sup>),



- 13) C(O)N(R<sup>41</sup>R<sup>42</sup>), and
- 14) a 4-, 5-, or 6-membered heterocyclic ring containing 1 nitrogen atom, unsubstituted, or mono-, di- or tri-substituted with -OH.

R<sup>2</sup>, R<sup>8</sup>, and R<sup>10</sup> are independently selected from hydrogen and halogen;:

R<sup>9</sup> is OCH<sub>3</sub> or OCHF<sub>2</sub>.

R<sub>4</sub>, R<sub>40</sub>, R<sub>41</sub>, R<sub>42</sub>, R<sub>46</sub>, R<sub>47</sub>, R<sub>48</sub>, R<sub>49</sub>, R<sub>50</sub>, R<sub>51</sub>, R<sub>52</sub>, and R<sub>53</sub> are independently selected from:

- 1) hydrogen,
- 2) C<sub>1</sub>-C<sub>6</sub> alkyl,
- 3) C<sub>3</sub>-C<sub>10</sub> cycloalkyl,
- 4) aryl,
- 5) R<sub>81</sub>,
- 6) CF<sub>3</sub>,
- 7) C<sub>2</sub>-C<sub>6</sub> alkenyl, and
- 8) C<sub>2</sub>-C<sub>6</sub> alkynyl,

said alkyl, aryl, and cycloalkyl is unsubstituted, mono-substituted with R<sub>18</sub>, di-substituted with R<sub>18</sub> and R<sub>19</sub>, tri-substituted with R<sub>18</sub>, R<sub>19</sub> and R<sub>20</sub>, or tetra-substituted with R<sub>18</sub>, R<sub>19</sub>, R<sub>20</sub> and R<sub>21</sub>;  
R<sub>5</sub> is independently selected from:

- 1) hydrogen,
- 2) halogen,
- 3) CN,
- 4) C(O)N(R<sub>49</sub>R<sub>50</sub>),
- 5) C(O)OR<sup>49</sup>,
- 6) S(O)<sub>0-2</sub>N(R<sub>49</sub>R<sub>50</sub>),
- 7) S(O)<sub>0-2</sub>R<sup>62</sup>,
- 8) C<sub>1</sub>-C<sub>6</sub> alkyl,
- 9) C<sub>3</sub>-C<sub>10</sub> cycloalkyl,
- 10) R<sub>82</sub>,

said alkyl, aryl, and cycloalkyl is unsubstituted, mono-substituted with R<sub>22</sub>, di-substituted with R<sub>22</sub> and R<sub>23</sub>, tri-substituted with R<sub>22</sub>, R<sub>23</sub> and R<sub>24</sub>, or tetra-substituted with R<sub>22</sub>, R<sub>23</sub>, R<sub>24</sub> and R<sub>25</sub>;  
R<sub>6</sub>, R<sub>60</sub>, R<sub>61</sub>, R<sub>62</sub> and R<sub>63</sub> are independently selected from:

- 1) C<sub>1</sub>-C<sub>6</sub> alkyl,
- 2) aryl,
- 3) R<sub>83</sub>, and
- 4) C<sub>3</sub>-C<sub>10</sub> cycloalkyl;

said alkyl, aryl, and cycloalkyl is unsubstituted, mono-substituted with R<sub>26</sub>, di-substituted with R<sub>26</sub> and R<sub>27</sub>, tri-substituted with R<sub>26</sub>, R<sub>27</sub> and R<sub>28</sub>, or tetra-substituted with R<sub>26</sub>, R<sub>27</sub>, R<sub>28</sub> and R<sub>29</sub>;  
R<sub>7</sub>, R<sub>15</sub>, R<sub>16</sub>, R<sub>17</sub>, R<sub>18</sub>, R<sub>19</sub>, R<sub>20</sub>, R<sub>21</sub>, R<sub>22</sub>, R<sub>23</sub>, R<sub>24</sub>, R<sub>25</sub>, R<sub>26</sub>, R<sub>27</sub>, R<sub>28</sub>, R<sub>29</sub>, and R<sub>70</sub> are independently selected from:

- 1) C<sub>1</sub>-C<sub>6</sub> alkyl,
- 2) halogen,

- 3) OR<sup>51</sup>,
- 4) CF<sub>3</sub>,
- 5) aryl,
- 6) C<sub>3</sub>-C<sub>10</sub> cycloalkyl,
- 7) R<sup>84</sup>,
- 8) S(O)<sub>0-2</sub>N(R<sup>51</sup>R<sup>52</sup>),
- 9) C(O)OR<sup>51</sup>,
- 10) C(O)R<sup>51</sup>,
- 11) CN,
- 12) C(O)N(R<sup>51</sup>R<sup>52</sup>),
- 13) N(R<sup>51</sup>)C(O)R<sup>52</sup>,
- 14) S(O)<sub>0-2</sub>R<sup>63</sup>,
- 15) NO<sub>2</sub>, and
- 16) N(R<sup>51</sup>R<sup>52</sup>);

R<sup>80</sup>, R<sup>81</sup>, R<sup>82</sup>, R<sup>83</sup> and R<sup>84</sup> are independently selected from a group of unsubstituted or substituted heterocyclic rings consisting of a 4-6 membered unsaturated or saturated monocyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting N, O and S, and a 9- or 10-membered unsaturated or saturated bicyclic ring with 1, 2, 3 or 4 heteroatom ring atoms selected from the group consisting of N, O or S;

n, r, s and t are independently 0, 1, 2, 3, 4, 5 or 6;

u is 0, 1 or 2; and

v is 0, 1 or 2, wherein said compound is selected from the group consisting of

[(6-methoxy-4-phenylisoquinolin-3-yl)methyl]dimethylamine,

1-(1-chloro-6-methoxy-4-phenylisoquinolin-3-yl)-N,N-dimethylmethanamine,

{[6-methoxy-1-(methylthio)-4-phenylisoquinolin-3-yl]methyl} dimethylamine,

[6-methoxy-1-(methylsulfonyl)-4-phenylisoquinolin-3-yl]methyl(dimethyl)amine oxide,

1-[6-methoxy-1-(methylsulfonyl)-4-phenylisoquinolin-3-yl]-N,N-dimethylmethanamine,

3-[(dimethylamino)methyl]-6-methoxy-4-phenylisoquinoline-1-carbonitrile,

2,3-Dimethyl-6-methoxy-4-phenylisoquinolinium hydroxide,

6-methoxy-1-(2-methoxyethoxy)-3-methyl-4-phenylisoquinoline,

{3-[(6-methoxy-3-methyl-4-phenylisoquinolin-1-yl)oxy]propyl} amine,

2-[(6-methoxy-3-methyl-4-phenylisoquinolin-1-yl)amino]ethanol,  
6-methoxy-3-methyl-1-(methylsulfonyl)-4-phenylisoquinoline,  
6-methoxy-N-(2-methoxyethyl)-3-methyl-4-phenylisoquinolin-1-amine,  
N-(6-methoxy-3-methyl-4-phenylisoquinolin-1-yl)ethane-1,2-diamine,  
6-methoxy-3-methyl-4-phenylisoquinoline,  
N-(3,4-dimethoxybenzyl)-6-methoxy-3-methyl-4-phenylisoquinolin-1-amine,  
6-methoxy-3-methyl-4-phenylisoquinolin-1-amine,  
1-(ethylsulfonyl)-6-methoxy-3-methyl-4-phenylisoquinoline,  
1-(benzylsulfonyl)-6-methoxy-3-methyl-4-phenylisoquinoline,  
6-methoxy-3-methyl-4-phenyl-1-(phenylsulfonyl)isoquinoline,  
6-methoxy-3-methyl-4-phenylisoquinoline-1-carbonitrile,  
3-tert-butyl-6-methoxy-1-(2-methoxyethoxy)-4-phenylisoquinoline,  
1-chloro-6-methoxy-4-phenylisoquinoline-3-carbonitrile,  
6-methoxy-4-phenylisoquinoline-1,3-dicarbonitrile,  
1-(allyloxy)-6-methoxy-4-phenylisoquinoline-3-carbonitrile,  
1-(2,3-dihydroxypropoxy)-6-methoxy-4-phenylisoquinoline-3-carbonitrile,  
(allylamino)-6-methoxy-4-phenylisoquinoline-3-carbonitrile,  
(+/-)-1-[(2,3-dihydroxypropyl)amino]-6-methoxy-4-phenylisoquinoline-3-carbonitrile,  
1-{[(2S)-2,3-dihydroxypropyl]amino}-6-methoxy-4-phenylisoquinoline-3-carbonitrile,  
1-{[(2R)-2,3-dihydroxypropyl]amino}-6-methoxy-4-phenylisoquinoline-3-carbonitrile,  
(+/-)-1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-6-methoxy-4-phenylisoquinoline-3-  
carbonitrile,  
1-{[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy}-6-methoxy-4-phenylisoquinoline-3-  
carbonitrile,  
1-{[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy}-6-methoxy-4-phenylisoquinoline-3-  
carbonitrile,

1-{[(2R)-2,3-dihydroxypropyl]oxy}-6-methoxy-4-phenylisoquinoline-3-carbonitrile,  
1-{[(2S)-2,3-dihydroxypropyl]oxy}-6-methoxy-4-phenylisoquinoline-3-carbonitrile,  
(+/-)-1-{[2,3-dihydroxypropyl]oxy}-6-methoxy-4-phenylisoquinoline-3-carbonitrile,  
1-[(3R)-3-hydroxypyrrolidin-1-yl]-6-methoxy-4-phenylisoquinoline-3-carbonitrile,  
1-[(3S)-3-hydroxypyrrolidin-1-yl]-6-methoxy-4-phenylisoquinoline-3-carbonitrile,  
(+/-)-1-[3-hydroxypyrrolidin-1-yl]-6-methoxy-4-phenylisoquinoline-3-carbonitrile,  
1-[cis-3,4-dihydroxypyrrolidin-1-yl]-6-methoxy-4-phenylisoquinoline-3-carbonitrile,  
6-methoxy-4-phenyl-1-pyrrolidin-1-ylisoquinoline-3-carbonitrile,  
6-methoxy-1-(methylsulfonyl)-4-phenylisoquinoline-3-carbonitrile,  
6-methoxy-4-phenylisoquinoline-3-carbonitrile,  
1,6-dimethoxy-4-phenylisoquinoline-3-carbonitrile,  
1-chloro-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,  
4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,  
4-(3-fluorophenyl)-6-methoxy-1-methylisoquinoline-3-carbonitrile,  
4-(3-fluorophenyl)-1-[(2-hydroxyethyl)amino]-6-methoxyisoquinoline-3-carbonitrile,  
1-amino-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,  
4-(3-fluorophenyl)-1-[(3-hydroxypropyl)amino]-6-methoxyisoquinoline-3-carbonitrile,  
1-(but-3-enyloxy)-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,  
(+/-)-1-(2,3-dihydroxypropoxy)-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,  
1-[(2R)-2,3-dihydroxypropoxy]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,  
1-[(2S)-2,3-dihydroxypropoxy]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,  
(+/-)-1-(3,4-dihydroxybutoxy)-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,  
(+/-)-1-[(3R)-3,4-dihydroxybutoxy]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,  
1-[(3S)-3,4-dihydroxybutoxy]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,  
(+/-)-1-[(1,4-dioxan-2-ylmethyl)amino]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-  
carbonitrile,

1-[(1,4-dioxan-(2R)-2-ylmethyl)amino]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-[(1,4-dioxan-(2S)-2-ylmethyl)amino]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

4-(3-fluorophenyl)-6-methoxy-1-[(1-methyl-1H-imidazol-4-yl)methoxy]isoquinoline-3-carbonitrile,

(+/-)-1-(1,3-dioxolan-4-ylmethoxy)-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-(1,3-dioxolan-(4R)-4-ylmethoxy)-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-(1,3-dioxolan-(4S)-4-ylmethoxy)-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-(1,3-dioxan-5-yloxy)-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

4-(3-fluorophenyl)-1-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-6-methoxyisoquinoline-3-carbonitrile,

4-(3-fluorophenyl)-1-(1H-imidazol-5-ylmethoxy)-6-methoxyisoquinoline-3-carbonitrile,

1-{[(2R)-2,3-dihydroxypropyl]amino}-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-{[(2S)-2,3-dihydroxypropyl]amino}-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

(+/-)-1-{[2,3-dihydroxypropyl]amino}-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-(1H-imidazol-1-yl)-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

6-methoxy-4-phenyl-1-[(pyridin-2-ylmethyl)amino]isoquinoline-3-carbonitrile,

6-methoxy-4-phenyl-1-[(2-pyridin-2-ylethyl)amino]isoquinoline-3-carbonitrile,

(+/-)-1-[(3,4-dihydroxybutyl)amino]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-[(3R)-(3,4-dihydroxybutyl)amino]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-

carbonitrile,

1-[(3S)-(3,4-dihydroxybutyl)amino]-4-(3-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-chloro-4-(2-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

4-(2-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

(+/-)-1-[(2,3-dihydroxypropyl)amino]-4-(2-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-[(2S)-(2,3-dihydroxypropyl)amino]-4-(2-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

1-[(2R)-(2,3-dihydroxypropyl)amino]-4-(2-fluorophenyl)-6-methoxyisoquinoline-3-carbonitrile,

(+/-)-6-(difluoromethoxy)-1-{[2,3-dihydroxypropyl]amino}-4-(3-fluorophenyl)isoquinoline-3-carbonitrile,

6-(difluoromethoxy)-1-{[(2S)-2,3-dihydroxypropyl]amino}-4-(3-fluorophenyl)isoquinoline-3-carbonitrile,

6-(difluoromethoxy)-1-{[(2R)-2,3-dihydroxypropyl]amino}-4-(3-fluorophenyl)isoquinoline-3-carbonitrile,

(+/-)-6-(difluoromethoxy)-1-{[2,3-dihydroxypropyl]oxy}-4-(3-fluorophenyl)isoquinoline-3-carbonitrile,

6-(difluoromethoxy)-1-{[(2S)-2,3-dihydroxypropyl]oxy}-4-(3-fluorophenyl)isoquinoline-3-carbonitrile,

6-(difluoromethoxy)-1-{[(2R)-2,3-dihydroxypropyl]oxy}-4-(3-fluorophenyl)isoquinoline-3-carbonitrile,

1-(4-hydroxypiperidin-1-yl)-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

1-azetidin-1-yl-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

(+/-)-1-[trans-3,4-dihydroxypyrrolidin-1-yl]-6-methoxy-4-phenylisoquinoline-3-carbonitrile,

1-[(3R,4R)-3,4-dihydroxypyrrolidin-1-yl]-6-methoxy-4-phenylisoquinoline-3-carbonitrile,  
1-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]-6-methoxy-4-phenylisoquinoline-3-carbonitrile, and  
6-methoxy-N-(3-methoxypropyl)-3-methyl-4-phenylisoquinolin-1-amine.

8. (withdrawn) A method of treating a condition in a mammal, the treatment of which is effected or facilitated by Kv1.5 inhibition, which comprises administering a compound of Claim 1 in an amount that is effective at inhibiting Kv1.5.

9. (withdrawn) A method of Claim 8, wherein the condition is cardiac arrhythmia.

10. (withdrawn) A method of Claim 9, wherein the cardiac arrhythmia is atrial fibrillation.

11. (withdrawn) A method of Claim 9, wherein the cardiac arrhythmia is selected from the group consisting of atrial flutter, atrial arrhythmia and supraventricular tachycardia.

12. (withdrawn) A method of preventing a condition in a mammal, the prevention of which is effected or facilitated by Kv1.5 inhibition, which comprises administering a compound of Claim 1 in an amount that is effective at inhibiting Kv1.5.

13. (withdrawn) A method of Claim 12, wherein the condition is cardiac arrhythmia.

14. (withdrawn) A method of Claim 13, wherein the cardiac arrhythmia is atrial fibrillation.

15. (withdrawn) A method of Claim 13, wherein the cardiac arrhythmia is selected from the group consisting of atrial flutter, atrial arrhythmia and supraventricular tachycardia.

16. (withdrawn) A method of Claim 12, wherein the condition is a thromboembolic event.

17. (withdrawn) A method of Claim 16, wherein the thromboembolic event is a stroke.

18. (withdrawn) A method of Claim 12, wherein the condition is congestive heart failure.

19. (currently amended) A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and the compound Claim + 7 or a pharmaceutically acceptable salt thereof.

20. (currently amended) A pharmaceutical composition made by combining the compound of Claim + 7 and a pharmaceutically acceptable carrier.

21. (withdrawn) A method of treating cardiac arrhythmia comprising administering a compound of Claim 1 with a compound selected from one of the classes of compounds consisting of antiarrhythmic agents having Kv1.5 blocking activities, ACE inhibitors, angiotensin II antagonists, cardiac glycosides, L-type calcium channel blockers, T-type calcium channel blockers, selective and nonselective beta blockers, endothelin antagonists, thrombin inhibitors, aspirin, nonselective NSAIDs, warfarin, factor Xa inhibitors, low molecular weight heparin, unfractionated heparin, clopidogrel, ticlopidine, IIb/IIIa receptor antagonists, 5HT receptor antagonists, integrin receptor antagonists, thromboxane receptor antagonists, TAFI inhibitors and P2T receptor antagonists.

22. (withdrawn) A method for inducing a condition of normal sinus rhythm in a patient having atrial fibrillation, which comprises treating the patient with a compound of Claim 1.

23. (withdrawn) A method for treating tachycardia in a patient which comprises treating the patient with an antitachycardia device in combination with a compound of Claim 1.